Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Others

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

CompanyDrug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches
Company

Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches

CompanyDeals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

CompanyDeals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B
Company

Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B

CompanyDeals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M
Company

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M

Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year
Company

Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year

CompanyDrug

CStone’s Sugemalimab Wins ESMO [I, A] Recommendation – PD-L1 Inhibitor Targets Stage III NSCLC Consolidation Therapy in Europe

CompanyDrug

SinoMab BioScience Reports Positive Phase I Bridging Data for SM17 – First-in-Class IL-25 Receptor Antibody Advances Route Conversion

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success
Company

InnoCare Pharma Reports 2025 Profitability – Revenue Surges 135% to RMB 2.37B on Global BD Success